Ceftolozane-Tazobactam (Zerbaxa)

Indications

General Comments: FDA approved in 2015
- For use in combination with Metronidazole (Flagyl) IV (see Metronidazole, [[Metronidazole]])
Bacteroides Fragilis (see Bacteroides Fragilis, [[Bacteroides Fragilis]])
- However, it has limited activity against other anaerobes
Extended-Spectrum Beta Lactamase (ESBL) and AmpC-Producing Organisms
- Enterobacter Cloacae (see Enterobacter Cloacae, [[Enterobacter Cloacae]])
- Escherichia Coli (see Escherichia Coli, [[Escherichia Coli]])
- Klebsiella Oxytoca (see Klebsiella Oxytoca, [[Klebsiella Oxytoca]])
- Klebsiella Pneumoniae (see Klebsiella Pneumoniae, [[Klebsiella Pneumoniae]])
- Proteus Mirabilis (see Proteus Mirabilis, [[Proteus Mirabilis]])
Pseudomonas Aeruginosa (see Pseudomonas Aeruginosa, [[Pseudomonas Aeruginosa]])
- Superior to ceftazidime
- Ceftolozane enters Pseudomonas Aeruginosa independently of the OprD channel and therefore, is active against organisms with porin deficiencies or mutations
- Unregulated efflux has little effect on ceftolozane as ceftolozane is not a substrate for the efflux pumps commonly found in Pseudomonas Aeruginosa
Streptococcus Anginosus (see Streptococcus Anginosus Group, [[Streptococcus Anginosus Group]])
Streptococcus Constellatus (see Streptococcus Anginosus Group, [[Streptococcus Anginosus Group]])
Streptococcus Salivarius (see Streptococcus Salivarius Group, [[Streptococcus Salivarius Group]])

General Comments: FDA approved in 2015
Extended-Spectrum Beta Lactamase (ESBL) and AmpC-Producing Organisms
- Escherichia Coli (see Escherichia Coli, [[Escherichia Coli]])
- Klebsiella Pneumoniae (see Klebsiella Pneumoniae, [[Klebsiella Pneumoniae]])
- Proteus Mirabilis (see Proteus Mirabilis, [[Proteus Mirabilis]])
Pseudomonas Aeruginosa (see Pseudomonas Aeruginosa, [[Pseudomonas Aeruginosa]])
- Superior to ceftazidime
- Ceftolozane enters Pseudomonas Aeruginosa independently of the OprD channel and therefore, is active against organisms with porin deficiencies or mutations
- Unregulated efflux has little effect on ceftolozane as ceftolozane is not a substrate for the efflux pumps commonly found in Pseudomonas Aeruginosa

Staphylococcus Aureus (see Staphylococcus Aureus, [[Staphylococcus Aureus]])
Enterococcus (see Enterococcus, [[Enterococcus]])

Renally eliminated (almost entirely by glomerular filtration), and its clearance is not affected by the addition of tazobactam (active renal tubular secretion)

IV: 1.5 g q8hrs (in combination with metronidazole for complicated intra-abdominal infection)